stockrow
Monday 9 November 2026
Export INO’s income statement to Excel — free account
Inovio Pharmaceuticals, Inc.
INOInovio Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $65,300.00, down 70.0% from fiscal 2024.
- Revenue
- −83.2%
- EPS
- +88.5%
- Free cash flow
- +13.4%
Quarter to June 2026, against a year earlier
1.22
0.23
−15.86%
Follow INO
Alert me
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
2 | 4 | 2 | 2 | 3 | 2 | 2 | 4 | 2 | 1 |
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
14.63 | 9.06 | 12.14 | 79.19 | 185.17 | 587.16 | 35.34 | 180.43 | 70.12 | 211.46 |
Altman Z-Score |
1.86 | 0.02 | (3.24) | (7.78) | 8.33 | 2.00 | (5.96) | (13.77) | (23.34) | (36.80) |
Altman Z″-Score (non-manufacturers) |
(5.49) | (5.16) | (15.55) | (19.06) | 4.36 | (2.61) | (13.11) | (30.07) | (51.27) | (85.44) |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
P/Operating CF |
(34.72) | (27.43) | (21.41) | (23.70) | (26.79) | (27.50) | (9.98) | (5.71) | (2.53) | (4.21) |
Beneish M-Score |
(1.60) | (3.52) | (3.82) | (3.03) | 2.28 | (4.47) | 0.10 | (3.11) | (2.51) | — |
P/B ratio |
4.19 | 2.68 | 4.25 | 60.25 | 2.98 | 2.61 | 1.63 | 1.28 | 0.73 | 3.39 |
Price to Tangible BV |
4.92 | 3.04 | 5.16 | 0.00 | 3.07 | 2.70 | 1.73 | 1.41 | 0.86 | 6.01 |
EV/Sales |
11.67 | 6.04 | 9.47 | 76.15 | 132.14 | 369.46 | 12.31 | 25.77 | (39.21) | 102.86 |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.25 | 0.00 |
EV/Operating CF |
(6.60) | (4.04) | (3.93) | (3.20) | (5.50) | (3.04) | (0.58) | (0.17) | 0.27 | (0.45) |
EV/FCF |
(6.30) | (3.51) | (3.86) | (3.19) | (5.48) | (3.03) | (0.58) | (0.18) | 0.27 | (0.45) |
Quick Ratio |
2.77 | 3.78 | 2.42 | 2.86 | 10.33 | 6.23 | 2.73 | 3.47 | 2.70 | 1.34 |
Current Ratio |
2.84 | 3.91 | 2.49 | 2.94 | 11.30 | 6.82 | 3.25 | 3.60 | 2.77 | 1.40 |
Net Debt/EBITDA |
1.44 | 1.60 | 0.91 | 0.12 | 3.29 | 1.31 | 0.90 | 1.14 | 0.85 | 0.70 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 53.51% | 3.46% | 3.02% | 4.77% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 14.25 | 0.04 | 0.04 | 0.07 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.18 | 0.23 | 0.19 | 0.03 | 0.02 | 0.00 | 0.02 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
0.85 | 0.72 | 0.76 | 0.82 | 1.07 | 0.71 | 0.77 | 0.92 | 0.97 | 1.04 |
Capex/Depreciation |
(0.88) | (2.45) | (0.41) | (0.18) | (0.33) | (0.19) | (0.23) | 0.37 | (0.30) | (0.10) |
Interest Coverage |
— | (3,229.46) | — | (13.98) | (14.26) | (155.56) | (213.38) | (117.71) | (632.16) | — |
| (49.27%) | (66.35%) | (84.50%) | (258.25%) | (71.34%) | (70.55%) | (89.97%) | (79.55%) | (115.42%) | (183.47%) | |
| (38.05%) | (48.87%) | (60.92%) | (86.79%) | (48.68%) | (58.64%) | (66.27%) | (52.02%) | (75.49%) | (90.61%) | |
ROIC |
(256.00%) | (347.05%) | (1,013.93%) | 0.00% | (113.79%) | (1,413.97%) | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
(82.12%) | (72.73%) | (141.63%) | (159.18%) | (37.75%) | (75.88%) | (123.76%) | (116.98%) | (162.10%) | (425.11%) |
Average Days of Receivables |
171.00 | 56.11 | 48.55 | 180.38 | 938.89 | 1,651.84 | 417.49 | 1,055.17 | 2,009.51 | 0.00 |
Research and Development Expense of Revenue |
250.82% | 233.47% | 312.51% | 2,140.55% | 1,271.66% | 14,043.29% | 1,828.54% | 10,417.86% | 34,720.06% | 83,012.10% |
Selling, General and Administrative Expense of Revenue |
67.55% | 67.01% | 96.17% | 661.57% | 502.59% | 3,028.65% | 878.80% | 5,719.00% | 16,986.36% | 50,046.86% |
Intangible Assets out of Total Assets |
0.10 | 0.09 | 0.12 | 0.10 | 0.03 | 0.03 | 0.04 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
29.63% | 30.96% | 34.95% | 265.12% | 211.13% | 1,483.93% | 219.79% | 1,330.83% | 3,028.05% | 5,751.61% |
Graham Net Nets |
0.14 | 0.24 | 0.12 | (0.14) | 0.29 | 0.34 | 0.52 | 0.66 | 1.07 | 0.13 |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Earnings Yield |
(14.15%) | (22.87%) | (26.01%) | (36.68%) | (12.55%) | (29.07%) | (77.66%) | (90.39%) | (220.54%) | (110.63%) |
Free Cash Flow Yield |
(12.66%) | (19.00%) | (20.23%) | (30.11%) | (13.02%) | (20.74%) | (59.84%) | (78.38%) | (208.64%) | (108.01%) |
Revenue per Share |
5.80 | 6.20 | 3.95 | 0.50 | 0.57 | 0.10 | 0.52 | 0.04 | 0.01 | 0.00 |
Operating CF per Share |
(10.26) | (9.28) | (9.54) | (11.90) | (13.77) | (12.40) | (10.87) | (5.61) | (3.83) | (1.89) |
Capex per Share |
(0.48) | (1.36) | (0.27) | (0.12) | (0.12) | (0.07) | (0.05) | 0.27 | (0.02) | (0.01) |
Free Cash Flow per Share |
(10.74) | (10.64) | (9.81) | (12.02) | (13.89) | (12.47) | (10.92) | (5.34) | (3.85) | (1.90) |
Cash per Share |
17.18 | 18.71 | 10.54 | 10.89 | 31.86 | 23.06 | 12.72 | 6.55 | 3.47 | 1.25 |
Shareholders Equity per Share |
20.23 | 20.92 | 11.29 | 0.66 | 35.69 | 22.97 | 11.18 | 5.29 | 2.52 | 0.51 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
20.23 | 20.92 | 11.29 | 0.66 | 35.69 | 22.97 | 11.18 | 5.29 | 2.52 | 0.51 |
Free Cash Flow |
(65.49) | (72.50) | (75.64) | (98.84) | (179.50) | (216.94) | (217.18) | (118.47) | (104.51) | (88.92) |
Working Capital |
80.77 | 102.96 | 52.52 | 62.21 | 429.46 | 382.70 | 218.37 | 110.54 | 62.50 | 17.45 |
Capital Expenditures |
(2.94) | (9.29) | (2.08) | (0.99) | (1.52) | (1.23) | (0.97) | 5.90 | (0.43) | (0.29) |
Net Current Asset Value |
74.27 | 93.61 | 43.73 | (44.35) | 392.54 | 352.17 | 189.07 | 99.51 | 53.14 | 10.91 |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.25 | 0.00 |
Capex to Sales |
0.08 | 0.22 | 0.07 | 0.24 | 0.21 | 0.69 | 0.09 | (7.09) | 1.97 | 4.38 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.37 | 0.21 | 0.32 | 0.43 | 0.41 | 0.36 | 0.54 | 3.23 | 0.39 | 1.18 |
Cash ROIC |
(28.71%) | (26.86%) | (44.95%) | (57.48%) | (20.14%) | (26.59%) | (44.15%) | (45.11%) | (64.26%) | (107.63%) |
Accounts Receivable Turnover |
2.96 | 3.66 | 5.78 | 1.35 | 0.70 | 0.13 | 1.04 | 0.12 | 0.12 | 0.00 |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
— | — | — | — | — | 0.00 | 0.00 | — | — | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
— | — | — | — | — | 0.00 | 0.00 | — | — | — |
Average Receivables |
11.95 | 11.53 | 5.27 | 3.04 | 10.55 | 13.55 | 9.89 | 7.07 | 1.80 | — |
Average Payables |
16.95 | 22.44 | 24.16 | 21.54 | 20.41 | 35.02 | 64.55 | 50.91 | 19.23 | 14.34 |
Average Assets |
193.77 | 180.47 | 159.18 | 137.53 | 341.86 | 517.86 | 422.24 | 259.74 | 142.07 | 93.75 |
Average Common Equity |
149.66 | 132.93 | 114.76 | 46.22 | 233.27 | 430.41 | 311.02 | 169.86 | 92.93 | 46.30 |
Columns are period end dates · fundamentals updated 26 Oct 2026